In this randomized controlled trial of patients with heart failure and mildly decreased or preserved ejection fraction, ...

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...

PASCAL repair offers lasting TR reduction, better survival, and improved quality of life in severe tricuspid regurgitation.

Explore how deep learning enables automated extraction of NYHA classes and heart failure symptoms, enhancing heart failure ...

A CRISPR-Cas9-based investigational therapy was linked with a drop in serum transthyretin (TTR) levels in patients with ...

The preliminary data open the door to an alternative approach to invasive monitoring in heart failure patients.

USA: The REALIZE-K trial shows that a daily oral potassium binder can safely enable the use of mineralocorticoid receptor ...

The current expanded analysis included sensitivity analyses of the primary endpoints, 6-minute walk distance(6MWD), EQ-5D-5L health state index, Patient Global Impression of Severity Overall ...

A group of Abbott HeartMates gathered in Buffalo to meet Damar Hamlin and build community around heart health during the ...

Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today ...

Scpharmaceuticals ( (SCPH) ) has released its Q3 earnings. Here is a breakdown of the information Scpharmaceuticals presented to its investors.

NYHA class III/IV Dilated (ischemic or idiopathic) cardiomyopathy Sinus rhythm >/= 55 bpm QRS >/= 120 ms PR interval >/= 150 ms ...